Inhibition of PD-1 protein by the CRISPR-Cas9 method as antitumor therapy of non-small cell lung cancers
Lung carcinoma is the second most common type of tumor in the world. Among them, 85% of the cases are of non-small cell lung cancer (NSCLC). It is known that, in general, NSCLC tumor cells proliferate due to a reduction in the cytotoxic T lymphocyte response. In the immune response to tumors, the in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Portuguese |
| Published: |
Pontifícia Universidade Católica de São Paulo
2019-06-01
|
| Series: | Revista da Faculdade de Ciências Médicas de Sorocaba |
| Subjects: | |
| Online Access: | http://revistas.pucsp.br/RFCMS/article/view/38943 |
| Summary: | Lung carcinoma is the second most common type of tumor in the world. Among them, 85% of the cases are of non-small cell lung cancer (NSCLC). It is known that, in general, NSCLC tumor cells proliferate due to a reduction in the cytotoxic T lymphocyte response. In the immune response to tumors, the interaction of the programmed death ligand 1 (PD-L1), expressed in tumor cells and the programmed cell death protein 1 (PD-1), expressed in cytotoxic T lymphocytes, promotes suppression of the immune response, leading to inhibition of the activation of cytotoxic T lymphocytes. Despite the biological therapies that have proven effective for the treatment of lung tumors, studies seek a genetic treatment option, such as the CRISPR/Cas9 method. This review aims to provide an update of the CRISPR-Cas9 method and its application as a therapeutic tool in NSCLC to deactivate the gene encoding the PD-1 protein. The genetic alteration of PD-1 protein by CRISPR-Cas9 can affect the interaction between receptor and ligand, allowing cytotoxic T lymphocytes to recognize and exert an antitumor response to NSCLC tumors. |
|---|---|
| ISSN: | 1517-8242 1984-4840 |